Despite medical advancements, many multiple myeloma patients still face limited treatment options due to relapse or resistance. High-intensity therapies are often out of reach for a large subset of patients, leaving them vulnerable. Clinical-stage biotech company CellCentric aims to close this gap with inobrodib, a novel, oral therapy designed for convenience and effectiveness.
Inobrodib, a first-in-class small molecule, disrupts cancer-driving genes by targeting p300 and CBP—key transcriptional coactivators. This action directly impacts the expression of genes like MYC and IRF4, which are critical in driving multiple myeloma. Unlike traditional hospital-administered therapies, inobrodib is taken orally, enabling at-home treatment with fewer side effects. This positions it as a practical choice for patients who can’t handle aggressive options.
The drug’s safety and simplicity stand out. Early clinical results presented at the American Society of Hematology (ASH) Annual Meeting showcased encouraging data, leading the FDA to grant both Fast Track and orphan drug status in 2023. This recognition highlights inobrodib’s potential to transform how myeloma is managed, especially for patients ineligible for other therapies.
To fuel its mission, CellCentric has raised $120 million in Series C funding. The round was co-led by RA Capital Management and Forbion, a new backer with a strong record in biotech investment. Additional support came from Avego Bioscience Capital and BrightEdge, the American Cancer Society’s venture arm.
This funding is a major step forward. It will allow CellCentric to begin Phase II/III trials for inobrodib in heavily pretreated myeloma patients, with hopes of securing accelerated approval. A global Phase III study is also in the works, expected to launch by mid-2026.
Strategic Trials and New Frontiers for Inobrodib
CellCentric plans to expand inobrodib’s use in other treatment settings. Starting in Q2 2025, the company will explore combining inobrodib with bispecific antibodies. It also aims to evaluate its role as a maintenance therapy, a critical need in keeping myeloma in remission.
These studies are part of a broader vision: positioning inobrodib as a key therapy across the entire spectrum of multiple myeloma care—from frontline to relapse.
CellCentric was founded on the groundbreaking work of Professor Azim Surani, a renowned developmental biologist from the University of Cambridge. His research on epigenetics and cell fate helped shape the company’s mission to tackle cancer at the molecular level.
Now operating in both the UK and the U.S., CellCentric has built an international team focused on creating innovative therapies. In early 2025, the company expanded to the U.S. with a new office in Burlington, Massachusetts. This move strengthens its presence in the Boston biotech hub and supports its clinical and regulatory operations.
A Vision for the Future of Cancer Treatment
For CEO Will West, the recent funding is more than financial backing—it’s a vote of confidence in the company’s approach. “We are delighted to secure the investment required to advance inobrodib fully and as effectively as possible,” he said. “This is a significant raise in a challenging market and a testament to the data we have in hand.”
New board member Jasper Bos, General Partner at Forbion, shares that enthusiasm. “CellCentric has developed an innovative and impactful therapy with inobrodib. It shows promising efficacy and a manageable safety profile in early trials. We are proud to support its advancement into registration studies.”
As CellCentric accelerates toward pivotal trials, inobrodib stands out as a potential game-changer for multiple myeloma. With strong clinical data, regulatory backing, and global investor confidence, this oral drug may soon become a new standard for patients who have long needed better options.
